Investors in Pharmaceutical Manufacturing

Bayer G4A is a healthcare accelerator that offers investment, mentoring, and networking opportunities for startups and developers. G4A is Bayer’s digital health partnerships and investments team dedicated to scaling digital health. Our team’s vision is to reach health for all through digital health.

UCB Ventures is a €150 million strategic corporate venture fund. UCB is a global biopharmaceutical company focused on neurology and immunology disorders, driven by innovative science to enhance patient lives worldwide. We work closely and forge strong connections with patients, caregivers, health care professionals and other stakeholders who know the challenges of these diseases and where the unmet needs are found all too well.

Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to develop tomorrow’s standard of care to cure cancer & infectious diseases and improve patient quality of life.